Theralink Technologies Inc's Business Segments

Theralink Technologies, Inc., previously known as OncBioMune Pharmaceuticals, Inc., was a clinical-stage biopharmaceutical company that focused on developing novel cancer immunotherapy products and had a proprietary vaccine technology. On June 5, 2020, Theralink Technologies, Inc. acquired the assets of Avant Diagnostics, Inc., a commercial-stage precision medicine and molecular data-generating company that focuses on the development and commercialization of patented proprietary data-generating assays, through the Asset Sale Transaction. The company purchased substantially all of the assets of Avant, and assumed some of its liabilities. In consideration for the Asset Sale Transaction, Theralink Technologies, Inc. issued to Avant 1,000 shares of a newly created Series D-1 Preferred Stock, which held 54.55% of all voting rights on an as-converted basis with the common stock. Upon the effectiveness of an increase of the Company’s authorized shares of common stock from 6,666,667 shares to 12,000,000,000 shares, all such shares of Series D-1 Preferred Stock issued to Avant automatically converted into 5,081,549,184 shares of the Company’s common stock. Avant possessed majority voting control of the Company immediately following the Asset Sale Transaction, and controlled the Company’s Board of Directors after the termination of the ten-day waiting period required by Rule 14f-1 under the Exchange Act. Therefore, the Asset Sale Transaction was accounted for as an asset acquisition of the Company’s net assets by Avant and a recapitalization of Avant. On June 5, 2020, Theralink Technologies, Inc. entered into an employment agreement with Dr. Michael Ruxin to serve as the company’s Chief Executive Officer, President and a director, entered into an employment agreement with Jeffery Busch to serve as the company’s Chairman of the Board of Directors, and appointed Yvonne Fors to its Board of Directors, pursuant to the Asset Purchase Agreement. On August 14, 2020, the Board appointed Mr. Andrew Kucharchuk as Acting Chief Financial Officer of the Company, and approved a change in the Company’s fiscal year-end from December 31 to September 30, effective immediately for the current fiscal year, and for all subsequent years until such time as the Board resolves to amend such fiscal year-end. The fiscal year has been changed to conform to the September 30 fiscal year-end of Avant, which is the historical registrant as a result of the Asset Sale Transaction consummated on June 5, 2020, and therefore, no transition report is required. On September 24, 2020, Andrew Kucharchuk resigned from his position as Acting Chief Financial Officer. Mr. Kucharchuk continues to serve as a director on the Company’s Board of Directors. On the same day, the Company appointed Thomas E. Chilcott, III, to serve as the Chief Financial Officer. On April 1, 2022, the Board of Directors was expanded to six members, and Danica Holley and Matthew Schwartz were appointed to these newly created positions. Theralink Technologies, Inc. is a commercial-stage, precision medicine, molecular data-generating company that focuses on the development and commercialization of a series of proprietary data-generating assays that may provide important actionable information for physicians, patients and biopharmaceutical companies, in the area of oncology. The Company aims to commercialize the technology originally developed by Theranostics Health, Inc. The technology is differentiated due to the exclusive license agreement with George Mason University (“GMU”), the patent portfolio licensed from GMU and the National Institute of Health (“NIH”), access to GMU’s well-p. In addition to its current product offerings, Theralink is also actively pursuing the development of new products, with a focus on expanding its precision oncology offerings. The company is working to develop assays that can be used to identify specific molecular targets that are associated with various types of cancer, with the goal of enabling more targeted and effective treatments for patients. Theralink has also established partnerships with other companies in the biopharmaceutical industry, in order to leverage its proprietary technology to support drug development and clinical trials. Through these partnerships, Theralink aims to generate additional revenue streams and expand the reach of its technology into new areas of oncology research and treatment. Overall, Theralink Technologies is a cutting-edge biopharmaceutical company with a focus on precision medicine and molecular data-generating assays for the diagnosis and treatment of cancer. With a strong patent portfolio and a team of experienced industry professionals, the company is well-positioned for continued growth and success in the years to come.

Theralink Technologies Inc. is a dynamic biotechnology company dedicated to improving precision medicine within the realm of cancer treatment. Through a focused approach that embraces advanced molecular diagnostics, comprehensive gene expression profiling, and tailored therapy selection, Theralink is at the forefront of revolutionizing cancer care.

Segments

Theralink Technologies primarily operates in the healthcare sector, specifically targeting the oncology domain. The company’s mission revolves around enhancing cancer treatment outcomes by developing innovative molecular diagnostic tests and bioinformatics platforms. Each segment of their operations is designed to support healthcare providers by delivering cutting-edge solutions that facilitate accurate diagnosis, develop personalized treatment strategies, and ultimately improve patient care.

Key segments include:

1. Molecular Diagnostics: This segment encompasses the development of tests that analyze biological samples to provide insights into the genetic and molecular makeup of tumors.

2. Bioinformatics: Theralink employs sophisticated data analytics to interpret complex biological data, aiding in the understanding and application of tumor genomics in clinical settings.

3. Personalized Cancer Treatment: By leveraging advanced diagnostic insights, Theralink helps clinicians tailor individual treatment plans, ensuring that therapies align with the specific genetic profile of each patient’s cancer.

Products

Theralink Technologies Inc. offers a range of proprietary products that enhance the precision oncology landscape. Key products include:

1. Theralink Oncology Test Suite: This flagship offering is a multifaceted, multi-omic tumor profiling platform specifically designed for solid tumors. It employs an integrated approach, combining genomic sequencing, transcriptomic profiling, and proteomic analysis to provide clinicians with a detailed molecular characterization of tumors. The insights gained from this test facilitate informed decision-making regarding optimal therapeutic strategies.

2. Cynvenio LiquidBiopsye: A revolutionary blood-based test that detects circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). This non-invasive approach allows for real-time monitoring of genetic alterations associated with the tumor, enabling clinicians to assess treatment efficacy and make adjustments as needed without the necessity of invasive biopsies.

Services

In addition to its product offerings, Theralink Technologies provides a comprehensive suite of services designed to bolster precision oncology efforts:

1. Bioinformatics and Data Analytics: Theralink’s analytics solutions offer robust capabilities for processing and interpreting molecular data derived from their oncology test suite. These advanced analytics empower healthcare providers with actionable insights to inform clinical decisions.

2. Physician Training and Education: Recognizing the importance of knowledge transfer, Theralink offers extensive training programs for healthcare providers. These programs are focused on maximizing the utility of molecular diagnostics and understanding the nuances of precision medicine, thus equipping clinicians with the necessary skills to interpret test results effectively.

3. Personalized Therapy Selection: This service delivers tailored treatment plans that harmonize with each patients unique genetic profile. Theralink integrates advanced molecular diagnostic findings with current treatment guidelines to devise individualized therapy strategies, ensuring that patients receive the most appropriate and effective treatment options based on their tumor characteristics.

Summary

In conclusion, Theralink Technologies Inc. stands as a leader in the arena of precision oncology, offering an array of innovative products and services. The Theralink Oncology Test Suite serves as the cornerstone of their product line, providing comprehensive tumor profiling to inform treatment decisions. Complementing this, the Cynvenio LiquidBiopsye offers a non-invasive method to monitor cancer progression. Theralinks commitment to enhancing cancer care is reflected in its robust analytics solutions, physician education programs, and personalized therapy services—all aimed at improving patient outcomes through the power of advanced molecular diagnostics and tailored treatment strategies.